2C-AL

In this article, we will address the topic of 2C-AL from different perspectives with the aim of delving into its importance and relevance today. 2C-AL is a topic that has aroused growing interest in various sectors and a detailed analysis can shed light on its many facets. Throughout the next few lines, we will explore the different aspects of 2C-AL, presenting different opinions and approaches that will allow the reader to fully understand the complexity and significance of this topic. Through a multidisciplinary approach, we will delve into the consequences and challenges posed by 2C-AL, thus offering a comprehensive vision that will contribute to the knowledge and understanding of this phenomenon.

2C-AL
Identifiers
  • 2-(2,5-dimethoxy-4-prop-2-enylphenyl)ethanamine
CAS Number
PubChem CID
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCN)OC)CC=C
  • InChI=1S/C13H19NO2/c1-4-5-10-8-13(16-3)11(6-7-14)9-12(10)15-2/h4,8-9H,1,5-7,14H2,2-3H3
  • Key:QNVPDGCJKPQARD-UHFFFAOYSA-N

2C-AL is a drug from the substituted phenethylamine family which acts as an agonist of the 5-HT2A receptor, with an EC50 of 2.15nM at 5-HT2A vs 77.71nM at 5-HT2B, and produces a head-twitch response in animal studies. It was first discussed as a hypothetical compound in Daniel Trachsel's 2013 review of the field after his successful synthesis of the related compounds 2C-V and 2C-YN,[1] and finally synthesised by a team at Gilgamesh Pharmaceuticals in 2020 using a different synthetic route from that employed by Trachsel.[2]

See also

References

  1. ^ Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. p. 768. ISBN 978-3-03788-700-4.
  2. ^ WO 2022/006186, Kruegel AC, "Phenalkylamines and Methods of Treating Mood Disorders" 



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.